Live, virtual CME training through WebExJoin to learn about screening, diagnosing, and treating OUD, including harm reduction tools. Hosted by: Maryland Addiction Consultation Service (MACS) Audience: Primary Care Physicians, Advance Practice Registered Nurses, Physician Assistants Learning Objectives:
- Review the integration of SUD treatment and primary care
- Review the Medications for Opioid Use Disorder, including features, initiations, maintenance, and safety
- Describe the process of buprenorphine initiation as well as stabilization and maintenance
- Describe how to take a patient history and evaluation
- Discuss the importance of harm reduction
Presenter:
Mike Fingerhood, MD Consultant, Maryland Addiction Consultation Service (MACS) Associate Professor of medicine and public health, Johns Hopkins University Event contact: Bridget Sweeney, MACS Training Coordinator MACSTraining@som.umaryland.edu CME Credit: The AAFP has reviewed Opioid Use Disorder Treatment Integrated with Primary Care, and deemed it acceptable for AAFP credit. Term of approval is from 04/28/2022 to 04/27/2023. Physicians should claim only the credit commensurate with the extent of their participation in the activity. This session is approved for 2 Online Only, Live AAFP Prescribed Credits. AAFP Prescribed credit is accepted by the American Medical Association as equivalent to AMA PRA Category 1 credit(s)™ toward the AMA Physician's Recognition Award. When applying for the AMA PRA, Prescribed credit earned must be reported as Prescribed, not as Category 1. CEU Credit: Maryland Addiction Consultation Service (MACS) of the University of Maryland School of Medicine, Department of Psychiatry is authorized as a sponsor of Continuing Education Units. MACS maintains responsibility for this program. MAT and MATE Acts:
On December 29, 2022, President Biden signed the fiscal year 2023 omnibus, passing the Mainstreaming Addiction Treatment (MAT) and Medication Access and Training Expansion (MATE) Acts. These bills were passed to expand access to buprenorphine for the treatment of opioid use disorder, and normalize and enhance substance use care across healthcare settings.
MACS is monitoring guidance from state and federal agencies closely and will update this page when more information becomes available. The resources on this page offer information about the omnibus, the bills, and the implications for healthcare providers and programs. Find out more here: https://www.marylandmacs.org/MAT--MATE-Acts/
